MAPT and Alzheimer disease: Future biologic identification may benefit from integration of specialized antibody databases (Therapeutic Antibody Database, Antibody Society repositories) and systematic assessment of BBB shuttle engineering potential for promising extracellular AD targets including Aβ oligomers, tau species, and neuroinflammatory mediators.